Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 2/2009

01.02.2009 | Editorial commentary

A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma

verfasst von: Paolo Zanotti-Fregonara, Gaia Grassetto, Elif Hindié, Domenico Rubello

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Excerpt

Thyroglobulin (Tg) measurements are the mainstay of the follow-up of patients with differentiated thyroid cancer. Reports of patients with a negative 131I whole-body scan (WBS) and positive Tg are common. Much less common are reports of patients with a positive 131I scan and negative stimulated Tg levels. …
Literatur
1.
Park EK, Chung JK, Lim IH, Park DJ, Lee DS, Lee MC, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2008; [Epub ahead of print]. doi:10.​1007/​s00259-008-0912-0
2.
Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82–7.PubMedCrossRef
3.
Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433–41.PubMedCrossRef
4.
Spencer CA. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004;89:3702–4.PubMedCrossRef
5.
Zanotti-Fregonara P, Hindié E, Keller I, Calzada-Nocaudie M, Devaux JY. Scintigraphic visualization of glossal thyroid tissue during the follow-up of thyroid cancer patients. Clin Nucl Med 2007;32:911–4.PubMedCrossRef
6.
Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005;153:651–9.PubMedCrossRef
7.
Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447–63.PubMedCrossRef
8.
Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:1448–52.PubMedCrossRef
9.
Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988–94.PubMed
10.
Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993;34:1626–31.PubMed
11.
Hindié E, Mellière D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003;30:974–81.PubMedCrossRef
12.
Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007;14:799–807.PubMedCrossRef
13.
Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003;89:1638–44.PubMedCrossRef
14.
Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504–15.PubMedCrossRef
15.
Rubello D, Casara D, Girelli ME, Piccolo M, Busnardo B. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J Nucl Med 1992;33:1478–80.PubMed
16.
Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707–11.PubMedCrossRef
17.
Brendel AJ, Lambert B, Guyot M, Jeandot R, Dubourg H, Roger P. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differentiated thyroid carcinoma. Eur J Nucl Med 1990;16:35–8.PubMedCrossRef
18.
Zanotti-Fregonara P, Khoury A, Duron F, Keller I, Christin-Maître S, Kiffel T. Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging 2007;34:541–6.PubMedCrossRef
19.
Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:112–21.PubMedCrossRef
Metadaten
Titel
A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma
verfasst von
Paolo Zanotti-Fregonara
Gaia Grassetto
Elif Hindié
Domenico Rubello
Publikationsdatum
01.02.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0963-2

Weitere Artikel der Ausgabe 2/2009

European Journal of Nuclear Medicine and Molecular Imaging 2/2009 Zur Ausgabe

Original Article

Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma

Letter to the Editor

Comment on: Recombinant human TSH in differentiated thyroid cancer: a nuclear medicine perspective

Letter to the Editor

Radiobiological considerations for radioembolization with 188Re-microspheres

Occasional Survey

Myocardial perfusion scintigraphy in Europe 2005

Original Article

Protocol for measuring myocardial blood flow by PET/CT in cats

Review Article

Multimodality molecular imaging — from target description to clinical studies